- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Rapid Progress in Bench-to-Clinic Reported for Several Cancers
The results were presented at the recent Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, a meeting jointly sponsored by the NCI, AACR, and EORTC.
A second investigational drug in the isocitrate dehydrogenase (IDH) inhibitor class has demonstrated activity in acute myeloid leukemia (AML), a small clinical study showed.
Seven of 14 patients with relapsed or refractory AML had objective responses to treatment with AG-120, an orally available inhibitor of IDH1. The clinical activity included four complete responses.
The drug has been well tolerated during the ongoing phase I trial to identify the optimal dose for continued clinical evaluation, Daniel Pollyea, MD, assistant professor of medicine at the University of Colorado in Denver, reported at the Symposium on Molecular Targets and Cancer Therapeutics in Barcelona.
Earlier this year, another small phase I study showed activity with the IDH2 inhibitor AG-221, which resulted in objective responses in six of seven patients with relapsed or refractory AML.
Link to the report on Medpage Today: http://bit.ly/1I9dX4R
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Texas Oncology to Roll Out Canopy for ePROs After Head-to-Head Pilot
March 18th 2025Debra Patt, MD, PhD, MBA, executive vice president of Public Policy and Strategy for Texas Oncology, said the practice received positive feedback from nurses and patients during a pilot that concluded in February.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
